{"entity":{"id":"nct06623136","kind":"trial","name":"A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of Toripalimab in non-small-cell lung cancer and small-cell lung cancer, run by Elpiscience (Suzhou) Biopharma, Ltd., now recruiting.","summary":"A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT06623136 by Elpiscience (Suzhou) Biopharma, Ltd., with 40 participants planned, started 2025-04-30 and due to reach its primary completion in 2027-02-28. Interventions recorded: ES102, Toripalimab. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06623136","url":"https://clinicaltrials.gov/study/NCT06623136"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["toripalimab"],"companies":["elpiscience-suzhou-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06623136","phase":"2","setting":"An Open-label, Multicenter, Single-arm Phase 2 Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer","sponsor":"Elpiscience (Suzhou) Biopharma, Ltd.","enrolled":40,"outcomes":[]},"route":"/trials/nct06623136/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"elpiscience-suzhou-biopharma","kind":"company","name":"Elpiscience (Suzhou) Biopharma","route":"/companies/elpiscience-suzhou-biopharma/"}]}}